Sucrosomial Iron
Phase 3Small molecule
Sucrosomial Iron is one of 51 small molecule programs targeting Randomized. It is currently in Phase 3.
3
Indications
7
Total Trials
2
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Randomized
#DrugCompanyPhaseTrials
1Rayos
RRoxane Laboratories
Phase 3
Tricor
JJagotec
Phase 3
Yondelis
AApotex Inc.
Phase 3
Methylthioninium Chloride
PProvepharm SAS
Phase 3
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rituxan
RochePhase 2
Zytiga
Johnson & JohnsonPhase 2
Erleada
Johnson & JohnsonPhase 2
Jaypirca
Eli LillyPhase 2
Clomid
FerringPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Heart Failure2 trials
Inflammatory Bowel Disease1 trial
Iron deficiency anemia1 trial
Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis
Unknown status·—·Phase 3·NCT05225545·30 enrolled
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sucrosomial Iron. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCardiochirurgia E.H.